Prognostic factors and survival in a prospective cohort of patients with high-grade glioma treated with carmustine wafers or temozolomide on an intention-to-treat basis

Acta Neurochirurgica

Volumn 154, Issue 2, 2012, Pages 211-222

  Catalán Uribarrena, Gregorio ^a,b   Bilbao Barandica, Gaizka ^a,b   Pomposo Gaztelu, Iñigo ^a,b   Undabeitia Huertas, José ^a   Ruiz De Gopegui Ruiz, Edurne ^a   Galbarriatu Gutiérrez, Lara ^a   Canales Llantada, Manuel ^a   Aurrecoechea Obieta, Jon ^a   Igartua Azkune, Alfonso ^a   Carbayo Lozano, Guillermo ^a  

^a HOSPITAL DE CRUCES   (Spain)

^b UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

Author keywords

Carmustine wafers; High grade glioma; Prognostic factors; Survival; Temozolomide

Indexed keywords

CARMUSTINE; TEMOZOLOMIDE;

ADJUVANT THERAPY; ADULT; AGE DISTRIBUTION; ARTICLE; ASTROCYTOMA; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRANIOTOMY; DRUG EFFICACY; DRUG FATALITY; GLIOBLASTOMA; GLIOSARCOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INTENTION TO TREAT ANALYSIS; KARNOFSKY PERFORMANCE STATUS; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; OLIGODENDROGLIOMA; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; SALVAGE THERAPY; SURVIVAL RATE; SURVIVAL TIME; SYSTEMIC THERAPY;

ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CARMUSTINE; CHEMOTHERAPY, ADJUVANT; COHORT STUDIES; DACARBAZINE; FEMALE; FOLLOW-UP STUDIES; GLIOMA; HUMANS; KARNOFSKY PERFORMANCE STATUS; MALE; MIDDLE AGED; NEOPLASM GRADING; PROGNOSIS; PROSPECTIVE STUDIES; RADIOTHERAPY, ADJUVANT; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 84856757345     PISSN: 00016268     EISSN: 09420940     Source Type: Journal    
DOI: 10.1007/s00701-011-1199-7     Document Type: Article

References (67)

1. ML Affronti JM Day JE Herndon II JN Rich JA Quinn DA Reardon JJ Vredenburgh A Desjardins RE McLendon HS Friedman 2007 Radiation and concurrent temozolomide followed by rotational multi-agent chemotherapy for glioblastoma (GBM) patients J Clin Oncol (Meeting Abstracts) 25 2068
2. ML Affronti CR Heery JE Herndon 2nd JN Rich DA Reardon A Desjardins JJ Vredenburgh AH Friedman DD Bigner HS Friedman 2009 Overall survival of newly diagnosed glioblastoma patients receiving carmustine wafers followed by radiation and concurrent temozolomide plus rotational multiagent chemotherapy Cancer 115 3501 3511 19514083 10.1002/cncr.24398 1:CAS:528:DC%2BD1MXpslOnurw%3D
3. FK Albert M Forsting K Sartor HP Adams S Kunze 1994 Early postoperative magnetic resonance imaging after resection of malignant glioma: objective evaluation of residual tumor and its influence on regrowth and prognosis Neurosurgery 34 45 60 8121569 10.1227/00006123-199401000-00008 1:STN:280:DyaK2c7ms12ksg%3D%3D discussion 60-41
4. Asher A (2007) Prospective Analysis of Temozolomide as Adjuvant to Gliadel and Radiation in Newly Diagnosed Malignant Glioma. American Association of Neurological Surgeons Annual Meeting; April 14-19, 2007; Washington, DC. Abstract 42860. American Association of Neurological Surgeons Annual Meeting; April 14-19, 2007; Washington, DC. Abstract 42860. Washington, DC, p Oral communication
5. H Athanassiou M Synodinou E Maragoudakis M Paraskevaidis C Verigos D Misailidou D Antonadou G Saris K Beroukas P Karageorgis 2005 Randomized phase II study of temozolomide and radiotherapy compared with radiotherapy alone in newly diagnosed glioblastoma multiforme J Clin Oncol 23 2372 2377 15800329 10.1200/JCO.2005.00.331 1:CAS:528:DC%2BD2MXjsVyhsrg%3D (Pubitemid 46218731)
6. FJ Attenello D Mukherjee G Datoo MJ McGirt E Bohan JD Weingart A Olivi A Quinones-Hinojosa H Brem 2008 Use of Gliadel (BCNU) wafer in the surgical treatment of malignant glioma: a 10-year institutional experience Ann Surg Oncol 15 2887 2893 18636295 10.1245/s10434-008-0048-2
7. GM Barbagallo MD Jenkinson AR Brodbelt 2008 'Recurrent' glioblastoma multiforme, when should we reoperate? Br J Neurosurg 22 452 455 18568742 10.1080/02688690802182256 (Pubitemid 351878614)
8. M Brada WK Yung 2000 Clinical trial end points in malignant glioma: need for effective trial design strategy Semin Oncol 27 11 19 10866345 1:STN:280:DC%2BD3czit1Oitg%3D%3D (Pubitemid 30390230)
9. AA Brandes E Franceschi A Tosoni V Blatt A Pession G Tallini R Bertorelle S Bartolini F Calbucci A Andreoli G Frezza M Leonardi F Spagnolli M Ermani 2008 MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients J Clin Oncol 26 2192 2197 18445844 10.1200/JCO.2007.14. 8163
10. AA Brandes L Nicolardi A Tosoni M Gardiman P Iuzzolino C Ghimenton M Reni A Rotilio G Sotti M Ermani 2006 Survival following adjuvant PCV or temozolomide for anaplastic astrocytoma Neuro Oncol 8 253 260 16723632 10.1215/15228517- 2006-005 1:CAS:528:DC%2BD28Xot1agtLo%3D (Pubitemid 46542650)
11. D Brandsma L Stalpers W Taal P Sminia MJ van den Bent 2008 Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas Lancet Oncol 9 453 461 18452856 10.1016/S1470-2045(08)70125-6 (Pubitemid 351597795)
12. H Brem S Piantadosi PC Burger M Walker R Selker NA Vick K Black M Sisti S Brem G Mohr P Muller R Morawetz SC Schold 1995 Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The polymer-brain tumor treatment group Lancet 345 1008 1012 7723496 10.1016/S0140-6736(95)90755-6 1:STN:280:DyaK2M3ktVansw%3D%3D
13. CBTRUS (2007) Annual Report. Published by the Central Brain Tumor Registry of the United States, 2007
14. J Concato N Shah RI Horwitz 2000 Randomized, controlled trials, observational studies, and the hierarchy of research designs N Engl J Med 342 1887 1892 10861325 10.1056/NEJM200006223422507 1:STN:280:DC%2BD3czgt1Chsw%3D%3D (Pubitemid 30419054)
15. WJ Curran Jr CB Scott J Horton JS Nelson AS Weinstein AJ Fischbach CH Chang M Rotman SO Asbell RE Krisch DF Nelson 1993 Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials J Natl Cancer Inst 85 704 710 8478956 10.1093/jnci/85.9.704 (Pubitemid 23133591)
16. S Cha 2009 Neuroimaging in neuro-oncology Neurotherapeutics 6 465 477 19560737 10.1016/j.nurt.2009.05.002 1:CAS:528:DC%2BD1MXhsFent7bP
17. W Dang T Daviau H Brem 1996 Morphological characterization of polyanhydride biodegradable implant gliadel during in vitro and in vivo erosion using scanning electron microscopy Pharm Res 13 683 691 8860422 10.1023/A:1016035229961 1:CAS:528:DyaK28XivFaqurk%3D (Pubitemid 26160095)
18. MC de Wit HG de Bruin W Eijkenboom PA Sillevis Smitt MJ van den Bent 2004 Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression Neurology 63 535 537 15304589 (Pubitemid 39031388)
19. AJ Domb M Rock C Perkin G Yipchuck B Broxup JG Villemure 1995 Excretion of a radiolabelled anticancer biodegradable polymeric implant from the rabbit brain Biomaterials 16 1069 1072 8519927 10.1016/0142-9612(95)98902-Q 1:CAS:528:DyaK2MXnvVKrs7o%3D
20. Garibi JM, Catalán G (2009) Gliadel en el mundo. Carmustina. Clinical Facts 2008. Publicaciones Permanyer Barcelona, pp 37-51
21. T Gorlia MJ van den Bent ME Hegi RO Mirimanoff M Weller JG Cairncross E Eisenhauer K Belanger AA Brandes A Allgeier D Lacombe R Stupp 2008 Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3 Lancet Oncol 9 29 38 18082451 10.1016/S1470-2045(07)70384-4
22. SA Grossman C Reinhard OM Colvin M Chasin R Brundrett RJ Tamargo H Brem 1992 The intracerebral distribution of BCNU delivered by surgically implanted biodegradable polymers J Neurosurg 76 640 647 1545259 10.3171/jns.1992.76.4.0640 1:CAS:528:DyaK38XisVWrt7g%3D
23. T Gupta R Sarin 2002 Poor-prognosis high-grade gliomas: evolving an evidence-based standard of care Lancet Oncol 3 557 564 12217793 10.1016/S1470-2045(02)00853-7 (Pubitemid 34993643)
24. S Gururangan L Cokgor JN Rich S Edwards ML Affronti JA Quinn JE Herndon 2nd JM Provenzale RE McLendon S Tourt-Uhlig JH Sampson V Stafford-Fox S Zaknoen M Early AH Friedman HS Friedman 2001 Phase I study of Gliadel wafers plus temozolomide in adults with recurrent supratentorial high-grade gliomas Neuro Oncol 3 246 250 11584894 1:CAS:528:DC%2BD38Xks1Olsrs%3D (Pubitemid 33674145)
25. Hart MG, Grant R, Garside R, Rogers G, Somerville M, Stein K (2008) Chemotherapeutic wafers for High Grade Glioma. Cochrane Database Syst Rev :CD007294
26. Hart MG, Grant R, Garside R, Rogers G, Somerville M, Stein K (2008) Temozolomide for high grade glioma. Cochrane Database Syst Rev:CD007415
27. A Hartz S Bentler M Charlton D Lanska Y Butani GM Soomro K Benson 2005 Assessing observational studies of medical treatments Emerg Themes Epidemiol 2 8 16137327 10.1186/1742-7622-2-8 (Pubitemid 41365579)
28. CR Heery A Desjardins JA Quinn JN Rich S Gururangan JJ Vredenburgh AH Friedman DA Reardon HS Friedman 2006 Acute toxicity analysis of patients receiving surgery, Gliadel wafer implantation, and postoperative daily temozolomide with radiation therapy for primary high-grade glioma J Clin Oncol (Meeting Abstracts) 24 11504
29. WF Hoffman VA Levin CB Wilson 1979 Evaluation of malignant glioma patients during the postirradiation period J Neurosurg 50 624 628 430157 10.3171/jns.1979.50.5.0624 1:STN:280:DyaE1M7ltlagsA%3D%3D (Pubitemid 9178240)
30. G Iliadis P Selviaridis A Kalogera-Fountzila A Fragkoulidi D Baltas N Tselis A Chatzisotiriou D Misailidou N Zamboglou G Fountzilas 2009 The Importance of Tumor Volume in the Prognosis of Patients with Glioblastoma Strahlenther Onkol 185 743 750 19899008 10.1007/s00066-009-2015-7
31. MD Jenkinson DG Du Plessis C Walker TS Smith 2007 Advanced MRI in the management of adult gliomas Br J Neurosurg 21 550 561 18071982 10.1080/02688690701642020 1:STN:280:DC%2BD2sjjsV2mug%3D%3D (Pubitemid 350249197)
32. LR Kleinberg J Weingart P Burger K Carson SA Grossman K Li A Olivi MD Wharam H Brem 2004 Clinical course and pathologic findings after Gliadel and radiotherapy for newly diagnosed malignant glioma: implications for patient management Cancer Invest 22 1 9 15069758 10.1081/CNV-120027575
33. RU Kothari T Brott JP Broderick WG Barsan LR Sauerbeck M Zuccarello J Khoury 1996 The ABCs of measuring intracerebral hemorrhage volumes Stroke 27 1304 1305 8711791 10.1161/01.STR.27.8.1304 1:STN:280:DyaK28zis1Gnug%3D%3D (Pubitemid 26286157)
34. A Kowalczuk RL Macdonald C Amidei G Dohrmann 3rd RK Erickson J Hekmatpanah S Krauss S Krishnasamy G Masters SF Mullan AJ Mundt P Sweeney EE Vokes BK Weir RL Wollman 1997 Quantitative imaging study of extent of surgical resection and prognosis of malignant astrocytomas Neurosurgery 41 1028 1036 9361056 10.1097/00006123-199711000-00004 1:STN:280:DyaK1c%2Fis12isg%3D%3D discussion 1036-1028 (Pubitemid 27475463)
35. Krzeminski JP, Piquer J, Riesgo P (2008) Repeated Implantation of Interstitial Chemotherapy to Treat Malignant Gliomas. Neurosurgery Quarterly 18:286-289 210.1097/WNQ.1090b1013e3181823144
36. RV La Rocca J Hodes WG Villanueva TW Vitaz DJ Morassutti MJ Doyle S Glisson A Cervera L Stribinskiene P New NS Litofsky 2006 A phase II study of radiation with concomitant and then sequential temozolamide (TMZ) in patients with newly diagnosed supratentorial high-grade malignant glioma who have undergone surgey with carmustine (BCNU) wafer insertion (Abstract TA-28) Neuro Oncol 8 445
37. RV La Rocca HM Mehdorn 2009 Localized BCNU chemotherapy and the multimodal management of malignant glioma Curr Med Res Opin 25 149 160 19210148 10.1185/03007990802611935
38. M Lacroix D Abi-Said DR Fourney ZL Gokaslan W Shi F DeMonte FF Lang IE McCutcheon SJ Hassenbusch E Holland K Hess C Michael D Miller R Sawaya 2001 A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival J Neurosurg 95 190 198 11780887 10.3171/jns.2001.95.2.0190 1:STN:280:DC%2BD38%2FlsFGitA%3D%3D (Pubitemid 32799739)
39. F Lefranc 2009 Editorial: on the road to multi-modal and pluri-disciplinary treatment of glioblastomas Acta Neurochir (Wien) 151 109 112 10.1007/s00701-009-0185-9
40. SH Lin LR Kleinberg 2008 Carmustine wafers: localized delivery of chemotherapeutic agents in CNS malignancies Expert Rev Anticancer Ther 8 343 359 18366283 10.1586/14737140.8.3.343 1:CAS:528:DC%2BD1cXjvF2lur0%3D (Pubitemid 351836283)
41. M.R.C.B.T.P. 2001 Randomized trial of procarbazine, lomustine, and vincristine in the adjuvant treatment of high-grade astrocytoma: a Medical Research Council trial J Clin Oncol 19 509 518
42. MJ McGirt KL Chaichana M Gathinji FJ Attenello K Than A Olivi JD Weingart H Brem AR Quinones-Hinojosa 2009 Independent association of extent of resection with survival in patients with malignant brain astrocytoma J Neurosurg 110 156 162 18847342 10.3171/2008.4.17536
43. MJ McGirt KD Than JD Weingart KL Chaichana FJ Attenello A Olivi J Laterra LR Kleinberg SA Grossman H Brem A Quinones-Hinojosa 2009 Gliadel (BCNU) wafer plus concomitant temozolomide therapy after primary resection of glioblastoma multiforme J Neurosurg 110 583 588 19046047 10.3171/2008.5.17557 1:CAS:528:DC%2BD1MXjvVyns7g%3D
44. RO Mirimanoff T Gorlia W Mason MJ Van den Bent RD Kortmann B Fisher M Reni AA Brandes J Curschmann S Villa G Cairncross A Allgeier D Lacombe R Stupp 2006 Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial J Clin Oncol 24 2563 2569 16735709 10.1200/JCO.2005.04.5963 1:CAS:528:DC%2BD28XmtVOmt70%3D (Pubitemid 46630635)
45. JM Nazzaro EA Neuwelt 1990 The role of surgery in the management of supratentorial intermediate and high-grade astrocytomas in adults J Neurosurg 73 331 344 2166779 10.3171/jns.1990.73.3.0331 1:STN:280:DyaK3czkslGjtg%3D%3D (Pubitemid 20260001)
46. M Ohki K Sakurada Y Sonoda S Sato S Saito T Kayama 2003 Analysis of the extent of astrocytic tumour resection evaluated by magnetic resonance images Neurosurg Rev 26 262 265 12820021 (Pubitemid 37248219)
47. JV Pesudo Martínez JM González-Darder R Feliú Tatay V Belloch Ugarte J Vera Roman JL Gil Salú 2001 Assessment of the degree of resection of high grade supratentorial gliomas with early postoperative magnetic resonance Neurocirugia (Astur) 12 43 50 (Pubitemid 32238394)
48. U Pichlmeier A Bink G Schackert W Stummer 2008 Resection and survival in glioblastoma multiforme: an RTOG recursive partitioning analysis of ALA study patients Neuro Oncol 10 1025 1034 18667747 10.1215/15228517-2008-052
49. M Prados 2001 Temozolomide in combination with other cytotoxic agents Semin Oncol 28 24 33 11550136 10.1016/S0093-7754(01)90068-5 1:CAS:528: DC%2BD3MXntFGht70%3D (Pubitemid 32879943)
50. MA Proescholdt C Macher C Woertgen A Brawanski 2005 Level of evidence in the literature concerning brain tumor resection Clin Neurol Neurosurg 107 95 98 15708222 10.1016/j.clineuro.2004.02.025 (Pubitemid 40228967)
51. T Ryken T Carlisle J Buatti P Kirby J Maley R Hohl BJ Smith J Greenlee M Frees M Rogers 2008 Treatment of adults with newly diagnosed glioblastoma multiforme or anaplastic astrocytoma with surgery, gliadel wafers and limited field radiation plus concomitant temozolomide followed by adjuvant temozolomide J Clin Oncol (Meeting Abstracts) 26 13003
52. Sabel M, Giese A (2008) Safety profile of carmustine wafers in malignant glioma: a review of controlled trials and a decade of clinical experience. Curr Med Res Opin
53. N Sanai MS Berger 2008 Glioma extent of resection and its impact on patient outcome Neurosurgery 62 753 764 18496181 10.1227/01.neu.0000318159. 21731.cf discussion 264-756
54. R Sawaya M Hammoud D Schoppa KR Hess SZ Wu WM Shi DM Wildrick 1998 Neurosurgical outcomes in a modern series of 400 craniotomies for treatment of parenchymal tumors Neurosurgery 42 1044 1055 9588549 10.1097/00006123-199805000- 00054 1:STN:280:DyaK1c3ksl2lsQ%3D%3D discussion 1055-1046 (Pubitemid 28196516)
55. SL Silverman 2009 From randomized controlled trials to observational studies Am J Med 122 114 120 19185083 10.1016/j.amjmed.2008.09.030
56. BM Spiegel E Esrailian L Laine MC Chamberlain 2007 Clinical impact of adjuvant chemotherapy in glioblastoma multiforme : a meta-analysis CNS Drugs 21 775 787 17696576 10.2165/00023210-200721090-00006 1:CAS:528:DC%2BD2sXhtFars7rJ (Pubitemid 47294722)
57. W Stummer A Novotny H Stepp C Goetz K Bise HJ Reulen 2000 Fluorescence-guided resection of glioblastoma multiforme by using 5-aminolevulinic acid-induced porphyrins: a prospective study in 52 consecutive patients J Neurosurg 93 1003 1013 11117842 10.3171/jns.2000.93.6.1003 1:CAS:528:DC%2BD3cXptValsro%3D (Pubitemid 32800611)
58. W Stummer U Pichlmeier T Meinel OD Wiestler F Zanella HJ Reulen 2006 Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial Lancet Oncol 7 392 401 16648043 10.1016/S1470-2045(06)70665-9 1:CAS:528: DC%2BD28XjvFWlsb0%3D
59. W Stummer HJ Reulen T Meinel U Pichlmeier W Schumacher JC Tonn V Rohde F Oppel B Turowski C Woiciechowsky K Franz T Pietsch 2008 Extent of resection and survival in glioblastoma multiforme: identification of and adjustment for bias Neurosurgery 62 564 576 18425006 10.1227/01.neu.0000317304.31579.17 discussion 564-576
60. R Stupp ME Hegi WP Mason MJ van den Bent MJ Taphoorn RC Janzer SK Ludwin A Allgeier B Fisher K Belanger P Hau AA Brandes J Gijtenbeek C Marosi CJ Vecht K Mokhtari P Wesseling S Villa E Eisenhauer T Gorlia M Weller D Lacombe JG Cairncross RO Mirimanoff 2009 Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial Lancet Oncol 10 459 466 19269895 10.1016/S1470-2045(09)70025-7 1:CAS:528: DC%2BD1MXlsVKhs74%3D
61. R Stupp WP Mason MJ van den Bent M Weller B Fisher MJ Taphoorn K Belanger AA Brandes C Marosi U Bogdahn J Curschmann RC Janzer SK Ludwin T Gorlia A Allgeier D Lacombe JG Cairncross E Eisenhauer RO Mirimanoff 2005 Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma N Engl J Med 352 987 996 15758009 10.1056/NEJMoa043330 1:CAS:528:DC%2BD2MXit1Wksbk%3D (Pubitemid 40349501)
62. S Valtonen U Timonen P Toivanen H Kalimo L Kivipelto O Heiskanen G Unsgaard T Kuurne 1997 Interstitial chemotherapy with carmustine-loaded polymers for high-grade gliomas: a randomized double-blind study Neurosurgery 41 44 48 9218294 10.1097/00006123-199707000-00011 1:STN:280:DyaK2szmtFCjsg%3D%3D discussion 48-49 (Pubitemid 27282080)
63. Van den Bent MJ, Stupp R, Mason W (2005) Impact of the extent of resection on overall survival in newly diagnosed glioblastoma after chemo-irradiation with temozolamide: further analysis of EORTC study 26981. Eur J Cancer Suppl 3:134 (abstr)
64. MD Walker TA Strike GE Sheline 1979 An analysis of dose-effect relationship in the radiotherapy of malignant gliomas Int J Radiat Oncol Biol Phys 5 1725 1731 231022 1:STN:280:DyaL3c7hsV2rsA%3D%3D (Pubitemid 10187518)
65. M Westphal DC Hilt E Bortey P Delavault R Olivares PC Warnke IR Whittle J Jaaskelainen Z Ram 2003 A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma Neuro Oncol 5 79 88 12672279 1:CAS:528:DC%2BD3sXjtVKltL4%3D (Pubitemid 36422560)
66. M Westphal Z Ram V Riddle D Hilt E Bortey 2006 Gliadel wafer in initial surgery for malignant glioma: long-term follow-up of a multicenter controlled trial Acta Neurochir (Wien) 148 269 275 10.1007/s00701-005-0707-z 1:STN:280:DC%2BD28znvFWmtQ%3D%3D discussion 275
67. MP Wu JA Tamada H Brem R Langer 1994 In vivo versus in vitro degradation of controlled release polymers for intracranial surgical therapy J Biomed Mater Res 28 387 395 8077254 10.1002/jbm.820280314 1:CAS:528:DyaK2cXit1Kksr0%3D (Pubitemid 24070733)